The novel selective inhibitors of cyclin-dependent kinase 4/6: in vitro and in silico study

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Cyclin-dependent kinase 4 and 6 (CDK4/6) are key cell cycle regulators.
• CDK4/6 inhibitors are FDA-approved for metastatic breast cancer.
• Developing selective CDK4/6 inhibitors is challenging due to conserved ATP binding sites.

Purpose of the Study:

• To analyze the in vitro selectivity and inhibitory activity of four previously identified potential CDK4/6 inhibitors.
• To further evaluate their development potential using in silico methods.
• To identify a lead compound for future drug development.

Main Methods:

• In vitro assays to assess selectivity and inhibitory activity against CDK4/6.
• In silico analysis to predict development potential.
• ADMET profiling compared to Palbociclib.

Main Results:

• All four compounds exhibited good selectivity for CDK4/6 due to structural similarity.
• ZINC585291674 showed the most potent inhibition with IC50 values of 184.14 nM (CDK4) and 111.78 nM (CDK6).
• The compounds' ADMET profiles were comparable to the reference drug Palbociclib.

Conclusions:

• ZINC585291674 is a promising lead compound for developing novel CDK4/6 inhibitors.
• The study validates the potential of ZINC585291674 for further preclinical and clinical development.
• This research contributes to the ongoing effort to find more effective treatments for breast cancer.